InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,616.84
(
-0.32%
)
US TECH 100
18,992.00
(
-1.08%
)
Dow Jones
41,240.52
(
0.16%
)
Brent Oil
80.24
(
-0.04%
)
Bitcoin
62,933.96
(
0.09%
)
Post# of 252977
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

dewophile

Send PM Follow Ignore
Followers 45
Posts 4652
Boards Moderated 0
Alias Born 07/19/2006

dewophile

Re: seschm post# 210429

Tuesday, 04/04/2017 12:36:54 PM

Tuesday, April 04, 2017 12:36:54 PM

Post# of 252977
Patients can be relapsers to rituxan based therapy and not totally refractory. some of these could have some tumor shrinkage when re-challanged to rituxan. how many i am not sure perhaps someone on here knows better than I. A durable response in this population probably means the TRIL drug is doing something since they did - after all - relapse to first line rituxan
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up